Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cisco Systems Inc (CSCO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Cisco Systems (CSCO) trades at $121.31, up 2.54% on the day, approaching its 52-week high with strong technical momentum. The stock shows bullish moving average signals and has consistently beaten earnings expectations in recent quarters. Recent AI cybersecurity partnerships and product launches, including Cisco Cloud Control, are driving positive sentiment. Valuation ratios remain elevated with a P/E of 40.44 and P/S of 7.96, reflecting growth expectations in networking and security segments.

Outlook remains positive with a consensus price target of $130.38, though high valuation multiples and competitive pressures pose risks. Revenue growth is projected to reach $60.7B in 2026 with improved margins. Institutional ownership is strong, but investors should monitor execution on AI initiatives and debt levels, which have increased recently.